<DOC>
	<DOCNO>NCT00253487</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , busulfan , O6-benzylguanine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . O6-benzylguanine may also help temozolomide work well make tumor cell sensitive drug . Radiation therapy use high-energy x-ray kill tumor cell . Giving chemotherapy peripheral stem cell transplant bone marrow transplant , use stem cell patient genetically-modified laboratory protect side effect chemotherapy , may allow chemotherapy give tumor cell kill . Giving combination chemotherapy radiation therapy together peripheral stem cell transplant bone marrow transplant may kill tumor cell . PURPOSE : This clinical trial study well give combination chemotherapy together radiation therapy work treat young patient undergo autologous stem cell transplant newly diagnose glioma .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Younger Patients Who Are Undergoing Autologous Stem Cell Transplant Newly Diagnosed Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility condition regimen comprise temozolomide , radiotherapy , busulfan follow infusion autologous stem cell genetically modify MGMT gene temozolomide O6-benzylguanine younger patient newly diagnose high-grade glioma . Secondary - Determine tolerability intrapatient dose escalation temozolomide , term transgene expression , patient treat regimen . - Determine , preliminarily , antitumor activity regimen patient . OUTLINE : This pilot study . - Surgery : Patients undergo biopsy surgical debulking tumor . Two six week later , patient proceed stem cell mobilization apheresis . - Autologous stem cell mobilization apheresis : Patients receive filgrastim ( G-CSF ) subcutaneously IV daily least 4 day apheresis continue apheresis complete . Patients undergo apheresis 4 consecutive day target number 5 X 10^6 CD34-positive peripheral blood stem cell ( PBSCs ) collect . Patients insufficient number PBSCs either undergo bone marrow harvest collect sufficient number cell remove study . The cell select CD34-positive cell cryopreserved later use . Patients proceed chemoradiotherapy . - Chemoradiotherapy : Patients receive oral temozolomide daily day 1-42 undergo radiotherapy daily , 5 day week , 6 week . Four eight week later , patient proceed low-intensity , nonmyeloablative conditioning regimen . - Autologous PBSC bone marrow transduction : Peripheral blood bone marrow CD34-positive stem cell transduce MGMT gene day -4 . - Low-intensity , nonmyeloablative condition regimen : Patients receive busulfan IV 2 hour day -3 -2 . Patients proceed autologous PBSC bone marrow infusion . - Autologous PBSC bone marrow infusion : Patients undergo autologous stem cell infusion use transduced PBSCs bone marrow day 0 . Three six week later , patient proceed chemotherapy . - Chemotherapy : Patients receive O6-benzylguanine IV 1 hour follow oral temozolomide daily day 1-5 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients experience unacceptable toxicity due O6-benzylguanine may receive temozolomide alone . Patients experience dose-limiting toxicity least 5 % transduce neutrophils peripheral blood analysis course 1 receive escalating dos ( intrapatient ) temozolomide course 2-6 . Some patient undergo second-look surgery first course chemotherapy . After completion study therapy , patient follow monthly 3 month , every 3 month 3 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 10 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose highgrade glioma 1 follow type : Glioblastoma multiforme WHO grade IV disease Anaplastic astrocytoma WHO grade III disease No lowgrade disease ( i.e. , WHO grade III disease ) No WHO grade III oligodendroglioma oligoastrocytoma Patients &gt; 30 year age undergone gross total resection nonmeasurable disease see postoperative MRI eligible Measurable disease , assess postoperative MRI , require patient ≤ 30 year age No tumor arise spine brainstem No metastatic disease spine PATIENT CHARACTERISTICS : Age 5 55 Performance status Karnofsky 50100 % ( patient 1130 year age ) OR Lansky 50100 % ( patient 510 year age ) Life expectancy At least 9 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 ( transfusion independent ) Hepatic Bilirubin ≤ 2.0 mg/dL ALT AST ≤ 2.5 time upper limit normal Albumin ≥ 2.0 g/dL Hepatitis B surface antigen core antibody negative Hepatitis C antibody negative Renal Creatinine normal OR Glomerular filtration rate ≥ 70 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficit must stable decrease No active infection HIV negative No serious illness medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Chemotherapy No prior chemotherapy Endocrine therapy Concurrent corticosteroid allow provide dose stable decrease Radiotherapy No prior radiotherapy Surgery See Disease Characteristics Other No concurrent investigational anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>